Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies

Nikki Agarwal, Brenda Cooper, Molly Gallogly, Leland Metheny, Changchun Deng, Ok-Kyong Chaekal, Rebecca Klisovic, Jane Reese, Dina Schneider, Rimas Orentas, Marcos de Lima, Koen van Besien, David Wald, Paolo Caimi, Ben Tomlinson

Blood (2025) 146 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2025-5925

Published: 2025

Journal Articles

Signaling role of viral protein motif and its application in CAR T cell therapy

Wooram Jung, Kunho Chung, Jude Franklin, David Wald, J. Joseph Melenhorst, Jae Jung

Blood (2025) 146 (Supplement 1): 5892.

https://doi.org/10.1182/blood-2025-5892

Published: 2025

Journal Articles

Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth

Huiqin Bian, Naseema Gangat, Na Shen, William Tse, David Wald, Ayalew Tefferi, Fei Yan, Shujun Liu

Blood (2025) 146 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2025-1990

Published: 2025

Journal Articles

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese, Armin Ghobadi, David Wald, Rimas Orentas, Boro Dropulic, Paolo Caimi, Marcos de Lima, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 567.

https://doi.org/10.1182/blood-2025-567

Published: 2025

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day

Ryan Stadel, Nethrie Idippily, Maria Florencia Giraudo, Paolo Caimi, Koen Van Besien, James Martin, John Wu, Changchun Deng, David Wald

Blood (2023) 142 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2023-188214

Published: 2023

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Journal Articles

Non-Invasive Tracking of Nanobubble Tagged Natural Killer Cells Using Clinical Ultrasound

Smitha Hosahalli Vasanna, Reshani Perera, Zachary Jackson, Eric Abenojar, Agata Exner, David Wald

Blood (2022) 140 (Supplement 1): 10283–10284.

https://doi.org/10.1182/blood-2022-167503

Published: 2022

Journal Articles

Oral Realgar- Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16

Huaiyu Wang, Shu Chen, Xiaojuan Zhang, Xinhua Lu, Sha Gong, David Wald, Haitao Zhang, Jing Li

Blood (2022) 140 (Supplement 1): 2014–2015.

https://doi.org/10.1182/blood-2022-166635

Published: 2022

Journal Articles

Downregulation of CD16 Surface Expression on NK Cells Is a Favorable Prognostic Factor in Acute Myeloid Leukemia

Huaiyu Wang, Xiaojuan Zhang, David Wald, Sha Gong, Wenjuan Wang, Jincheng Wang

Blood (2022) 140 (Supplement 1): 11834–11835.

https://doi.org/10.1182/blood-2022-168947

Published: 2022

Journal Articles

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Ryan Stadel, Ruifu Liu, Yosef Landesman, David Wald, Smitha Hosahalli Vasanna, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7413–7414.

https://doi.org/10.1182/blood-2022-164443

Published: 2022

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

Zachary Jackson, Changjin Hong, Robert Schauner, Boro Dropulic, Paolo F. Caimi, Marcos J.G. de Lima, Kalpana Gupta, Jane Reese, Tae Hyun Hwang, David Wald

Blood (2021) 138 (Supplement 1): 164.

https://doi.org/10.1182/blood-2021-152813

Published: 2021

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Grace Lee, Sheela Karunanithi, Zachary Jackson, David Wald, MD PhD

Blood (2019) 134 (Supplement_1): 3607.

https://doi.org/10.1182/blood-2019-131947

Published: 2019

Journal Articles

Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells

Ashish Sharma, Anne Roe, Filipa Blasco Lopes, Ruifu Liu, Jane Reese, Susan Pereira Ribeiro, Rafick-Pierre Sekaly, PhD, Marcos de Lima, MD, David Wald, MD PhD

Blood (2018) 132 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2018-99-120098

Published: 2018

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

Demonstration of a Single-Parameter, Rapid Flow Cytometry Assay in Assessing Natural Killer Cell Cytotoxic Function

Evelyn Ojo, BS, David Wald, MD PhD, Folashade Otegbeye, MBBChir, MPH

Blood (2017) 130 (Supplement 1): 2291.

https://doi.org/10.1182/blood.V130.Suppl_1.2291.2291

Published: 2017

Journal Articles

Targeting Leukocyte Derived MPO in Heart Failure

David Wald, PhD MD, Kalpana Gupta, PhD, Yuan Lu, MD, Stephen Moreton

Blood (2017) 130 (Supplement 1): 3570.

https://doi.org/10.1182/blood.V130.Suppl_1.3570.3570

Published: 2017

Journal Articles

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

James ignatz-Hoover, Isaac Ghansah, Masumi Ueda, MD, Victoria Wang, Hillard M Lazarus, MD, Marcos de Lima, MD, David Wald, PhD MD

Blood (2017) 130 (Supplement 1): 1226.

https://doi.org/10.1182/blood.V130.Suppl_1.1226.1226

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies

Signaling role of viral protein motif and its application in CAR T cell therapy

Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Non-Invasive Tracking of Nanobubble Tagged Natural Killer Cells Using Clinical Ultrasound

Oral Realgar- Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16

Downregulation of CD16 Surface Expression on NK Cells Is a Favorable Prognostic Factor in Acute Myeloid Leukemia

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Demonstration of a Single-Parameter, Rapid Flow Cytometry Assay in Assessing Natural Killer Cell Cytotoxic Function

Targeting Leukocyte Derived MPO in Heart Failure

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only